Tolmachov Oleg E
Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Artif Intell Med. 2015 Jan;63(1):1-6. doi: 10.1016/j.artmed.2014.11.001. Epub 2014 Dec 17.
Gene delivery in vivo that is tightly focused on the intended target cells is essential to maximize the benefits of gene therapy and to reduce unwanted side-effects. Cell surface markers are immediately available for probing by therapeutic gene vectors and are often used to direct gene transfer with these vectors to specific target cell populations. However, it is not unusual for the choice of available extra-cellular markers to be too scarce to provide a reliable definition of the desired therapeutically relevant set of target cells. Therefore, interrogation of intra-cellular determinants of cell-specificity, such as tissue-specific transcription factors, can be vital in order to provide detailed cell-guiding information to gene vector particles. An important improvement in cell-specific gene delivery can be achieved through auto-buildup in vector homing efficiency using intelligent 'self-focusing' of swarms of vector particles on target cells. Vector self-focusing was previously suggested to rely on the release of diffusible chemo-attractants after a successful target-specific hit by 'scout' vector particles.
I hypothesize that intelligent self-focusing behaviour of swarms of cell-targeted therapeutic gene vectors can be accomplished without the employment of difficult-to-use diffusible chemo-attractants, instead relying on the intra-swarm signalling through cells expressing a non-diffusible extra-cellular receptor for the gene vectors. In the proposed model, cell-guiding information is gathered by the 'scout' gene vector particles, which: (1) attach to a variety of cells via a weakly binding (low affinity) receptor; (2) successfully facilitate gene transfer into these cells; (3) query intra-cellular determinants of cell-specificity with their transgene expression control elements and (4) direct the cell-specific biosynthesis of a vector-encoded strongly binding (high affinity) cell-surface receptor. Free members of the vector swarm loaded with therapeutic cargo are then attracted to and internalized into the intended target cells via the expressed cognate strongly binding extra-cellular receptor, causing escalation of gene transfer into these cells and increasing the copy number of the therapeutic gene expression modules. Such self-focusing swarms of gene vectors can be either homogeneous, with 'scout' and 'therapeutic' members of the swarm being structurally identical, or, alternatively, heterogeneous (split), with 'scout' and 'therapeutic' members of the swarm being structurally specialized.
It is hoped that the proposed self-focusing cell-targeted gene vector swarms with receptor-mediated intra-swarm signalling could be particularly effective in 'top-up' gene delivery scenarios, achieving high-level and sustained expression of therapeutic transgenes that are prone to shut-down through degradation and silencing. Crucially, in contrast to low-precision 'general location' vector guidance by diffusible chemo-attractants, ear-marking non-diffusible receptors can provide high-accuracy targeting of therapeutic vector particles to the specific cell, which has undergone a 'successful cell-specific hit' by a 'scout' vector particle. Opportunities for cell targeting could be expanded, since in the proposed model of self-focusing it could be possible to probe a broad selection of intra-cellular determinants of cell-specificity and not just to rely exclusively on extra-cellular markers of cell-specificity. By employing such self-focusing gene vectors for the improvement of cell-targeted delivery of therapeutic genes, e.g., in cancer therapy or gene addition therapy of recessive genetic diseases, it could be possible to broaden a leeway for the reduction of the vector load and, consequently, to minimize undesired vector cytotoxicity, immune reactions, and the risk of inadvertent genetic modification of germline cells in genetic treatment in vivo.
体内基因传递精准聚焦于目标细胞对于最大化基因治疗效益并减少不良副作用至关重要。细胞表面标志物可立即被治疗性基因载体探测到,常被用于引导这些载体将基因转移至特定目标细胞群体。然而,可用的细胞外标志物选择往往过于稀少,无法为所需的治疗相关目标细胞集提供可靠定义,这种情况并不罕见。因此,探究细胞特异性的细胞内决定因素,如组织特异性转录因子,对于为基因载体颗粒提供详细的细胞引导信息可能至关重要。通过智能地使载体颗粒群在目标细胞上“自我聚焦”,提高载体归巢效率,可实现细胞特异性基因传递的重要改进。此前认为载体自我聚焦依赖于“侦察兵”载体颗粒成功靶向特定目标后释放可扩散的化学引诱剂。
我假设细胞靶向治疗性基因载体群的智能自我聚焦行为无需使用难以应用的可扩散化学引诱剂即可实现,而是依赖于通过表达基因载体的非可扩散细胞外受体在群内进行信号传递。在所提出的模型中,细胞引导信息由“侦察兵”基因载体颗粒收集,这些颗粒:(1)通过弱结合(低亲和力)受体附着于多种细胞;(2)成功促进基因转移至这些细胞;(3)利用其转基因表达控制元件查询细胞特异性的细胞内决定因素;(4)指导载体编码的强结合(高亲和力)细胞表面受体的细胞特异性生物合成。然后,装载治疗性货物的载体群中的游离成员通过表达的同源强结合细胞外受体被吸引并内化到预期目标细胞中,导致基因向这些细胞的转移增加,并增加治疗性基因表达模块的拷贝数。这种基因载体的自我聚焦群可以是同质的,群中的“侦察兵”和“治疗性”成员在结构上相同,或者是异质的(分裂的),群中的“侦察兵”和“治疗性”成员在结构上专门化。
希望所提出的具有受体介导的群内信号传递的自我聚焦细胞靶向基因载体群在“补充”基因传递方案中可能特别有效,实现治疗性转基因的高水平和持续表达,这些转基因容易因降解和沉默而关闭。至关重要的是,与可扩散化学引诱剂的低精度“大致定位”载体引导相比,标记非可扩散受体可将治疗性载体颗粒高精度靶向到特定细胞,该细胞已被“侦察兵”载体颗粒“成功进行细胞特异性命中”。细胞靶向的机会可能会扩大,因为在所提出的自我聚焦模型中,有可能探究广泛的细胞特异性细胞内决定因素,而不仅仅依赖于细胞特异性的细胞外标志物。通过使用这种自我聚焦基因载体来改善治疗性基因的细胞靶向传递,例如在癌症治疗或隐性遗传疾病的基因添加治疗中,有可能扩大减少载体负荷的余地,从而将不期望的载体细胞毒性、免疫反应以及体内基因治疗中生殖细胞意外基因修饰的风险降至最低。